October 25, 2011

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

MK-2206 was well tolerated, with evidence of AKT signaling blockade. Rational combination trials are ongoing to maximize clinical benefit with this therapeutic strategy.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Yap et al. (Tue,) studied this question.

synapsesocial.com/papers/69d8d4b32c87b79b92d17cf3 https://doi.org/https://doi.org/10.1200/jco.2011.35.5263

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ)2001 · 1,832 citations
2Abstract #3714: In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor2009 · 15 citations
3How Much Gets there and What Does it Do?: The Need for Better Pharmacokinetic and Pharmacodynamic Endpoints in Contemporary Drug Discovery and Development2003 · 152 citations
4High-throughput oncogene mutation profiling in human cancer2007 · 996 citations
5Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers2008 · 1,330 citations

Preguntar a la IA

Me gusta

Guardar